Conversation with The Cancer Letter
Lilly’s PACE Continuous Innovation Indicators
Visualize Progress and Value in Research
Lilly Oncology has launched a novel value assessment tool that aggregates 40 years of oncology data to measure progress and identify unmet needs in cancer treatments.
The tool, called PACE Continuous Innovation Indicators, or PACE CII, is an effort to visualize progress in cancer treatments with the flexibility to accommodate different cancer subtypes.
PACE CII, launched earlier this year, contains data on 12 solid tumors: namely cancers of the breast, colon, rectum, liver, pancreas, and prostate, as well as melanoma, non-small cell lung cancer, gastric cancer, renal cancer, testicular cancer and endometrial cancer.